Skip to main content
Top
Published in: Pituitary 2/2013

01-06-2013

Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile

Authors: S. Koutroumpi, V. Daidone, M. T. Sartori, M. G. Cattini, N. M. Albiger, G. Occhi, S. Ferasin, A. Frigo, F. Mantero, A. Casonato, C. Scaroni

Published in: Pituitary | Issue 2/2013

Login to get access

Abstract

A high incidence of venous thromboembolic (VTE) complications has been reported in Cushing’s syndrome (CS), mostly post-operatively and attributable to hypercoagulability. The prevalence of symptomatic VTE was investigated retrospectively in 58 consecutive CS patients in relation to acquired and genetic thrombotic risk factors. Eight CS patients (14 %) developed VTE (group A), 3 of them related and 5 unrelated to surgery. These patients had higher urinary free cortisol (p = 0.01) and VWF levels (p = 0.02) than the 50 patients without VTE (group B), as well an increase in the hemostatically more efficient, high-molecular-weight VWF multimers (p = 0.002). Factor V Leiden and the prothrombin gene 20210A variants (the most common inherited thrombophilic defects) were more represented in group A than in group B, as was the genotype GCAG/GCAG of the VWF gene promoter, known to hyperinduce VWF upregulation under cortisol excess. All but one of the patients with VTE unrelated to surgery had at least four acquired and at least one inherited risk factor. Severe hypercortisolism and VWF levels with increased haemostatic activity are strongly associated with VTE in CS. VTE episodes unrelated to surgery are attributable to the synergistic action of acquired and inherited thrombotic risk factors. Based on these observations, we believe that severely affected CS patients should be screened for coagulation disorders and receive antithrombotic prophylaxis whenever they have concomitant prothrombotic risk factors.
Literature
1.
go back to reference Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 23:145–150PubMed Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 23:145–150PubMed
2.
go back to reference Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A (1982) Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb Haemost 47:116–117PubMed Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A (1982) Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb Haemost 47:116–117PubMed
3.
go back to reference Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A (1985) Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 30:518–520 Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A (1985) Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 30:518–520
4.
go back to reference La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P, Angeli A (1997) Recurrent thromboembolism as a hallmark of Cushing’s syndrome. J Endocrinol Invest 20:211–214PubMed La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P, Angeli A (1997) Recurrent thromboembolism as a hallmark of Cushing’s syndrome. J Endocrinol Invest 20:211–214PubMed
5.
go back to reference Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, Patrassi GM, Girolami A (2003) The PAI-I gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 9:299PubMedCrossRef Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, Patrassi GM, Girolami A (2003) The PAI-I gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 9:299PubMedCrossRef
6.
go back to reference Blann AD (2006) Plasma Von Willebrand factor, thrombosis and the endothelium: the first 30 years; Review. Thromb Haemost 95:49–55PubMed Blann AD (2006) Plasma Von Willebrand factor, thrombosis and the endothelium: the first 30 years; Review. Thromb Haemost 95:49–55PubMed
7.
go back to reference Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW (2006) High Von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation and genetic variability. Stroke 37:2672–2677PubMedCrossRef Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW (2006) High Von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation and genetic variability. Stroke 37:2672–2677PubMedCrossRef
8.
go back to reference De Lange M, Snieder H, Ariens R, Spector TD, Grant PJ (2001) The genetics of haemostasis. Lancet 357:101–105PubMedCrossRef De Lange M, Snieder H, Ariens R, Spector TD, Grant PJ (2001) The genetics of haemostasis. Lancet 357:101–105PubMedCrossRef
9.
go back to reference Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A, Scaroni C (2008) Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 140:230–235PubMedCrossRef Casonato A, Daidone V, Sartorello F, Albiger N, Romualdi C, Mantero F, Pagnan A, Scaroni C (2008) Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 140:230–235PubMedCrossRef
10.
go back to reference Ageno W, Beccatini C, Brighton T, Selby R, Pieter W (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93–102PubMedCrossRef Ageno W, Beccatini C, Brighton T, Selby R, Pieter W (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93–102PubMedCrossRef
11.
go back to reference Rosendaal FR (2005) Venous thrombosis: the role of genes, environment, and behavior. Hematology American Society of Hematology. Education Program, pp 1–12 Rosendaal FR (2005) Venous thrombosis: the role of genes, environment, and behavior. Hematology American Society of Hematology. Education Program, pp 1–12
12.
go back to reference Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A (1999) Abnormalities of Von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coag Fibrinolysis 10:145–151CrossRef Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A (1999) Abnormalities of Von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coag Fibrinolysis 10:145–151CrossRef
13.
go back to reference Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 87:3662–3666PubMedCrossRef Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 87:3662–3666PubMedCrossRef
14.
go back to reference Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593–5602PubMedCrossRef
15.
go back to reference Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A (2002) Reduced von Willebrand factor survival in type vicenza von Willebrand disease. Blood 99:180–184PubMedCrossRef Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A (2002) Reduced von Willebrand factor survival in type vicenza von Willebrand disease. Blood 99:180–184PubMedCrossRef
16.
go back to reference Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A (1996) Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 75:422PubMed Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A (1996) Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 75:422PubMed
17.
go back to reference Simioni P, Tormene D, Manfrin D et al (1998) Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 103:1045PubMedCrossRef Simioni P, Tormene D, Manfrin D et al (1998) Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 103:1045PubMedCrossRef
18.
go back to reference Daidone V, Cattini MG, Pontara E, Sartorello F, Gallinaro L, Marotti A, Scaroni C, Pagnan A, Casonato A (2009) Microsatellite (GT)n repeats and SNPs in the Von Willebrand factor gene promoter do not influence circulating Von Willebrand factor levels under normal conditions. Thromb Haemost 101:298–304PubMed Daidone V, Cattini MG, Pontara E, Sartorello F, Gallinaro L, Marotti A, Scaroni C, Pagnan A, Casonato A (2009) Microsatellite (GT)n repeats and SNPs in the Von Willebrand factor gene promoter do not influence circulating Von Willebrand factor levels under normal conditions. Thromb Haemost 101:298–304PubMed
19.
go back to reference Mancini T, Kola B, Mantero F et al (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxford) 61:768–777CrossRef Mancini T, Kola B, Mantero F et al (2004) High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxford) 61:768–777CrossRef
20.
go back to reference Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MB, Fliers E, Gerdes VEA, Büller HR, Brandjes PM (2009) Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 94:2743–2750PubMedCrossRef Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MB, Fliers E, Gerdes VEA, Büller HR, Brandjes PM (2009) Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 94:2743–2750PubMedCrossRef
21.
go back to reference Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxford) 56:541–551CrossRef Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF (2002) Long term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxford) 56:541–551CrossRef
22.
go back to reference Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes of coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a retrospective study before and after surgery. Eur J Endocrinol 163:783–791PubMedCrossRef Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes of coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a retrospective study before and after surgery. Eur J Endocrinol 163:783–791PubMedCrossRef
23.
go back to reference Stuijver DJF, Van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525–3532PubMedCrossRef Stuijver DJF, Van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525–3532PubMedCrossRef
24.
go back to reference Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Zupancic Salek S, Jelcic J, Aganovic I, Korsic M (2009) Hypercoagulability in Cushing’s syndrome: the role of the specific haemostatic and fibrinolytic markers. Endocrine 39:70–74CrossRef Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Zupancic Salek S, Jelcic J, Aganovic I, Korsic M (2009) Hypercoagulability in Cushing’s syndrome: the role of the specific haemostatic and fibrinolytic markers. Endocrine 39:70–74CrossRef
25.
go back to reference Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JP, Folsom AR (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Inter Med 162:1182–1189CrossRef Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JP, Folsom AR (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Inter Med 162:1182–1189CrossRef
26.
go back to reference Heit JA, Leibson CL, Ashrani AA, Petterson TM, Baily RK, Melton LJ (2009) Is diabetes mellitus an independent risk factor for venous thromboembolism? A population-based case-control study. Arterioscler Thromb Vasc Biol 29:1399–1405PubMedCrossRef Heit JA, Leibson CL, Ashrani AA, Petterson TM, Baily RK, Melton LJ (2009) Is diabetes mellitus an independent risk factor for venous thromboembolism? A population-based case-control study. Arterioscler Thromb Vasc Biol 29:1399–1405PubMedCrossRef
27.
go back to reference Pranzy M, Jezkova J. Horova E, Lazarova V, Hana V, Kvasnicka L, Pecen L, Marek J, Skrha J, Ksrek M (2008) Impaired microvascular reactivity and endothelial function in patients with Cushing’s syndome: influence of arterial hypertension. Physiol Res 57:13–22 Pranzy M, Jezkova J. Horova E, Lazarova V, Hana V, Kvasnicka L, Pecen L, Marek J, Skrha J, Ksrek M (2008) Impaired microvascular reactivity and endothelial function in patients with Cushing’s syndome: influence of arterial hypertension. Physiol Res 57:13–22
28.
go back to reference Martens I, Considine RV, Van der Planken M, Van Gaal LF (2006) Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur J Endocrinol 155:477–484CrossRef Martens I, Considine RV, Van der Planken M, Van Gaal LF (2006) Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur J Endocrinol 155:477–484CrossRef
29.
go back to reference Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, Pabinger I (2007) Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 92:374–380PubMedCrossRef Ay C, Tengler T, Vormittag R, Simanek R, Dorda W, Vukovich T, Pabinger I (2007) Venous thromboembolism—a manifestation of the metabolic syndrome. Haematologica 92:374–380PubMedCrossRef
30.
31.
go back to reference Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504–1508PubMed Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504–1508PubMed
32.
go back to reference Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL (2004) G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thrombo Haemost 2:119–127CrossRef Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL (2004) G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thrombo Haemost 2:119–127CrossRef
33.
go back to reference Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N (2004) Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 103:2157–2161PubMedCrossRef Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N (2004) Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 103:2157–2161PubMedCrossRef
Metadata
Title
Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile
Authors
S. Koutroumpi
V. Daidone
M. T. Sartori
M. G. Cattini
N. M. Albiger
G. Occhi
S. Ferasin
A. Frigo
F. Mantero
A. Casonato
C. Scaroni
Publication date
01-06-2013
Publisher
Springer US
Published in
Pituitary / Issue 2/2013
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-012-0398-4

Other articles of this Issue 2/2013

Pituitary 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine